PT2623498E - Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida - Google Patents

Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida Download PDF

Info

Publication number
PT2623498E
PT2623498E PT118292531T PT11829253T PT2623498E PT 2623498 E PT2623498 E PT 2623498E PT 118292531 T PT118292531 T PT 118292531T PT 11829253 T PT11829253 T PT 11829253T PT 2623498 E PT2623498 E PT 2623498E
Authority
PT
Portugal
Prior art keywords
fluoro
hydroxy
sodium salt
pyrazine carboxamide
pyrazine
Prior art date
Application number
PT118292531T
Other languages
English (en)
Inventor
Keiko Takakura
Namika Nakamatsu
Sakiko Takeshima
Sayuri Uehara
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of PT2623498E publication Critical patent/PT2623498E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
PT118292531T 2010-09-30 2011-09-29 Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida PT2623498E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010221682 2010-09-30

Publications (1)

Publication Number Publication Date
PT2623498E true PT2623498E (pt) 2016-02-02

Family

ID=45893139

Family Applications (1)

Application Number Title Priority Date Filing Date
PT118292531T PT2623498E (pt) 2010-09-30 2011-09-29 Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida

Country Status (20)

Country Link
US (3) US20130274472A1 (pt)
EP (1) EP2623498B1 (pt)
JP (1) JPWO2012043700A1 (pt)
CN (1) CN103209966B (pt)
CY (1) CY1117041T1 (pt)
DK (1) DK2623498T3 (pt)
ES (1) ES2554630T3 (pt)
HK (1) HK1183015A1 (pt)
HR (1) HRP20151263T1 (pt)
HU (1) HUE026872T2 (pt)
MY (1) MY161429A (pt)
PH (1) PH12015501649A1 (pt)
PL (1) PL2623498T3 (pt)
PT (1) PT2623498E (pt)
RS (1) RS54408B1 (pt)
SG (1) SG189161A1 (pt)
SI (1) SI2623498T1 (pt)
SM (1) SMT201600072B (pt)
TW (1) TWI552998B (pt)
WO (1) WO2012043700A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
EP2623497B1 (en) * 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
BR112015014839B1 (pt) * 2012-12-22 2022-09-06 Kbp Biosciences Co., Ltd Forma cristalina do composto utilizado como antagonista do receptor de mineralocorticoide, seus usos, seu processo de preparação e composição farmacêutica
JP6487051B2 (ja) * 2014-12-30 2019-03-20 サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation ポリマーナノ粒子の凍結乾燥物、及びその製造方法
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
WO2018003946A1 (ja) * 2016-06-30 2018-01-04 富山化学工業株式会社 凍結乾燥製剤の製造方法
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN111556752A (zh) * 2017-12-28 2020-08-18 富士胶片富山化学株式会社 冻干制剂的制造方法
MX2021005691A (es) 2018-11-19 2021-07-07 Jazz Pharmaceuticals Ireland Ltd Formulaciones de farmacos resistentes al alcohol.
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN111249229B (zh) * 2020-03-10 2023-05-02 北京阜康仁生物制药科技有限公司 一种稳定的法匹拉韦注射液及其制备方法
TR202017792A2 (tr) * 2020-11-06 2021-01-21 Aroma Ilac Sanayi Ltd Sti 6-floro-3-hidroksi-2-pirazinkarboksamid etken maddesi veya sodyum tuzunu içeren liyofilizasyon tekniğiyle üretilen yeni bir farmasötik kompozisyon
CN112574130B (zh) * 2020-12-11 2021-10-15 山东大学 一种法匹拉韦药物共晶及其制备方法和应用
CN113750105A (zh) * 2020-12-11 2021-12-07 山东大学 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用
US20240041866A1 (en) 2020-12-18 2024-02-08 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition
EP4265252A1 (en) 2020-12-18 2023-10-25 FUJIFILM Toyama Chemical Co., Ltd. Pharmaceutical composition
WO2023033683A1 (ru) * 2021-09-06 2023-03-09 Общество С Ограниченной Ответственностью "Промомед Рус" Противовирусная фармацевтическая композиция, содержащая фавипиравир и аминокислоту
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736555B2 (en) 1998-01-07 2001-08-02 Meiji Seika Pharma Co., Ltd. A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof
CZ301763B6 (cs) 1998-08-20 2010-06-16 Toyama Chemical Co., Ltd. Protivirový prostredek a derivát dusíkatého heterocyklického karboxamidu
ATE294185T1 (de) 2000-02-16 2005-05-15 Toyama Chemical Co Ltd Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediäre zur herstellung der derivate
CN101610772B (zh) 2007-02-16 2013-01-16 富山化学工业株式会社 包含吡嗪衍生物的药物组合物和使用吡嗪衍生物的联合用药的方法
JP2008231064A (ja) 2007-03-23 2008-10-02 Nippon Shokubai Co Ltd カルバゾイルアルキル(メタ)アクリレートの製造方法
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
RU2470924C2 (ru) * 2007-09-27 2012-12-27 Тояма Кемикал Ко., Лтд. Органическая аминовая соль 6-фтор-3-гидрокси-2-пиразинкарбонитрила и способ ее получения
CN102348458B (zh) 2009-03-13 2013-11-06 富山化学工业株式会社 含有6-氟-3-羟基-2-吡嗪甲酰胺的片剂和粒状粉剂
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide

Also Published As

Publication number Publication date
PH12015501649B1 (en) 2015-10-05
PL2623498T3 (pl) 2016-05-31
JPWO2012043700A1 (ja) 2014-02-24
US20130274472A1 (en) 2013-10-17
EP2623498A4 (en) 2014-03-26
HK1183015A1 (en) 2013-12-13
HUE026872T2 (en) 2016-07-28
CY1117041T1 (el) 2017-04-05
TW201219375A (en) 2012-05-16
TWI552998B (zh) 2016-10-11
DK2623498T3 (en) 2016-02-22
US20150038713A1 (en) 2015-02-05
SI2623498T1 (sl) 2016-03-31
CN103209966B (zh) 2015-06-10
MY161429A (en) 2017-04-14
SG189161A1 (en) 2013-05-31
SMT201600072B (it) 2016-04-29
WO2012043700A1 (ja) 2012-04-05
US20150266831A1 (en) 2015-09-24
EP2623498A1 (en) 2013-08-07
CN103209966A (zh) 2013-07-17
PH12015501649A1 (en) 2015-10-05
HRP20151263T1 (hr) 2015-12-18
RS54408B1 (en) 2016-04-28
US9096547B2 (en) 2015-08-04
ES2554630T3 (es) 2015-12-22
EP2623498B1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
HK1183015A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
HK1183014A1 (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2-
HK1252424A1 (zh) 鈉葡萄糖協同轉運蛋白1的抑制劑
PL2742051T3 (pl) Amorficzna postać soli sodowej dolutegrawiru
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
IL232599A (en) Hydrobromide salt of peridofidine
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
ZA201209407B (en) Modification of xylan
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
ZA201302476B (en) Aluminum salt containing high percentage of al30
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
HK1210776A1 (en) Substituted sodium 1h-pyrazol-5-olate 1h--5-
GB0906379D0 (en) Reduced sodium salt
EP2922413A4 (en) SODIUM SODIUM COMPOSITIONS AND METHOD OF MANUFACTURE AND USE THEREOF
ZA201205320B (en) Preparation process of the sodium salt of esomeprazole
PT2542591T (pt) Derivados silílicos de polissacáridos
EP2688426A4 (en) SALT COMPOSITION WITH REDUCED SODIUM CONTENT
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
IL243320A0 (en) Intermediates of teroarylpiperidine and piperazine derivatives
GB2493855B8 (en) Reduced sodium salt
HUP1000616A2 (en) Process for preparation of rosuvastatin salt
HU1000688D0 (en) Use of trifluoro-phal
GB201216287D0 (en) Reduced sodium salt